Home » Stocks » VRCA

Verrica Pharmaceuticals Inc. (VRCA)

Stock Price: $13.53 USD -0.27 (-1.96%)
Updated Apr 23, 2021 9:44 AM EDT - Market open
Market Cap 373.11M
Revenue (ttm) n/a
Net Income (ttm) -42.69M
Shares Out 25.00M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 23
Last Price $13.53
Previous Close $13.80
Change ($) -0.27
Change (%) -1.96%
Day's Open 13.91
Day's Range 13.26 - 13.67
Day's Volume 2,044
52-Week Range 6.02 - 18.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic...

2 weeks ago - GlobeNewsWire

WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

3 weeks ago - GlobeNewsWire

WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical...

1 month ago - GlobeNewsWire

WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical intervent...

1 month ago - GlobeNewsWire

Torii to make upfront payment of $11.5 million to Verrica in addition to other potential milestone payments of up to $58 million and, if marketed in Japan, tiered transfer price payments as a percentage...

1 month ago - GlobeNewsWire

– FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 –

1 month ago - GlobeNewsWire

WEST CHESTER, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medic...

1 month ago - GlobeNewsWire

WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

2 months ago - GlobeNewsWire

- In new post hoc analyses of the Phase 3 molluscum trials segmenting molluscum lesions by body region and study visit, the percentage of participants with complete clearance of all baseline and new mol...

3 months ago - GlobeNewsWire

WEST CHESTER, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

3 months ago - GlobeNewsWire

- Verrica reaffirms expectation to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 - - Verrica reaffirms expectation to resubmit its New Drug App...

5 months ago - GlobeNewsWire

WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medica...

5 months ago - GlobeNewsWire

- 35 % of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2. 4 % for vehicle (p=0.0001) -

5 months ago - GlobeNewsWire

- Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 -

5 months ago - GlobeNewsWire

WEST CHESTER, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring med...

6 months ago - GlobeNewsWire

NEW YORK, Sept. 14, 2020 /PRNewswire/ --Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc.

7 months ago - PRNewsWire

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.

7 months ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Verrica Pharmaceuticals Inc.

7 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action fi...

7 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - September 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharm...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - September 10, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.

7 months ago - Newsfile Corp

BENSALEM, Pa., Sept. 10, 2020 /PRNewswire/ -- Law Offices of Howard G.

7 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - September 10, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharm...

7 months ago - Newsfile Corp

LOS ANGELES, Sept. 9, 2020 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 14, 2020 deadline to file a lead plaintiff motion in the class action filed on ...

7 months ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - September 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharmac...

7 months ago - Newsfile Corp

WEST CHESTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring med...

7 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - September 8, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Verrica Pharmaceuticals Inc.

7 months ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - September 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharmac...

7 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - August 25, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.

7 months ago - Newsfile Corp

WEST CHESTER, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medi...

8 months ago - GlobeNewsWire

- Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter -

8 months ago - GlobeNewsWire

Verrica Pharmaceuticals: The Fundamentals Aren't So Clear, But The Stock Chart May Be Telling Us Something

8 months ago - Seeking Alpha

New York, New York--(Newsfile Corp. - July 24, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.

8 months ago - Newsfile Corp

– Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company’s product candidates –

9 months ago - GlobeNewsWire

– Dr. Gary Goldenberg appointed Chief Medical Officer;  Dr. Brad Catalone assumes the role of Head of Drug Development –

9 months ago - GlobeNewsWire

New York, New York--(Newsfile Corp. - July 22, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc.

9 months ago - Newsfile Corp

New York, New York--(Newsfile Corp. - July 20, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Verrica Pharmaceuticals Inc.

9 months ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Verrica Pharmaceuticals, Inc. (N...

9 months ago - Business Wire

Los Angeles, California--(Newsfile Corp. - July 17, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Verrica Pharmaceuti...

9 months ago - Newsfile Corp

SAN DIEGO & WEST CHESTER, Pa.--(BUSINESS WIRE)---- $VRCA #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Verrica Pharmaceuticals Inc.

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc.

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #VRCA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Verrica Pharmaceuticals Inc.

9 months ago - Business Wire

New York, New York--(Newsfile Corp. - July 15, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. ("Verrica" or...

9 months ago - Newsfile Corp

BENSALEM, Pa.--(BUSINESS WIRE)---- $VRCA #classaction--Law Offices of Howard G.

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #VRCA--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Co...

9 months ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Eastern District of P...

9 months ago - Business Wire

– Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC) and Human Factors Information –

9 months ago - GlobeNewsWire

Verrica (VRCA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

LOS ANGELES--(BUSINESS WIRE)---- $VRCA #classaction--The Law Offices of Frank R. Cruz continues its investigation on behalf of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA) in...

9 months ago - Business Wire

About VRCA

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; which has completed phase II clinical trial for treating common warts; and that is in phase II clinical trial for the treatment of external genital warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agr... [Read more...]

Industry
Biotechnology
IPO Date
Jun 15, 2018
CEO
Ted White
Employees
29
Stock Exchange
NASDAQ
Ticker Symbol
VRCA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for VRCA stock is "Strong Buy." The 12-month stock price forecast is 20.83, which is an increase of 53.95% from the latest price.

Price Target
$20.83
(53.95% upside)
Analyst Consensus: Strong Buy